These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

433 related articles for article (PubMed ID: 28038727)

  • 21. New biomarkers and therapeutics can be discovered during COPD-lung cancer transition.
    Wang X
    Cell Biol Toxicol; 2016 Oct; 32(5):359-61. PubMed ID: 27405768
    [No Abstract]   [Full Text] [Related]  

  • 22. A Road Map to Personalizing Targeted Cancer Therapies Using Synthetic Lethality.
    Parameswaran S; Kundapur D; Vizeacoumar FS; Freywald A; Uppalapati M; Vizeacoumar FJ
    Trends Cancer; 2019 Jan; 5(1):11-29. PubMed ID: 30616753
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is Precision Medicine an Oxymoron?
    Eckhardt SG; Lieu C
    JAMA Oncol; 2019 Feb; 5(2):142-143. PubMed ID: 30419105
    [No Abstract]   [Full Text] [Related]  

  • 24. Precision Medicine in Pediatric Oncology.
    Vo KT; Parsons DW; Seibel NL
    Surg Oncol Clin N Am; 2020 Jan; 29(1):63-72. PubMed ID: 31757314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Precision Medicine and Targeted Therapies in Breast Cancer.
    Greenwalt I; Zaza N; Das S; Li BD
    Surg Oncol Clin N Am; 2020 Jan; 29(1):51-62. PubMed ID: 31757313
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evidence-Based Development and Clinical Use of Precision Oncology Therapeutics.
    Comment LA; Ward AF; Schrock AB; Fabrizio D; Venstrom JM; Hegde PS; Alexander BM
    Clin Pharmacol Ther; 2020 Sep; 108(3):440-443. PubMed ID: 32744335
    [No Abstract]   [Full Text] [Related]  

  • 27. [Individualization of anticancer therapy; molecular targets of novel drugs in oncology].
    Regulska K; Stanisz B; Regulski M
    Postepy Hig Med Dosw (Online); 2012 Nov; 66():855-67. PubMed ID: 23175342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Editorial overview: cancer: from target discovery to targeted therapy: the risky business of target validation.
    Cruzalegui F
    Curr Opin Pharmacol; 2014 Aug; 17():iv-vi. PubMed ID: 25220882
    [No Abstract]   [Full Text] [Related]  

  • 29. Anticipating designer drug-resistant cancer cells.
    Frangione ML; Lockhart JH; Morton DT; Pava LM; Blanck G
    Drug Discov Today; 2015 Jul; 20(7):790-3. PubMed ID: 25697478
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Steps forward for cancer precision medicine.
    Salgado R; Moore H; Martens JWM; Lively T; Malik S; McDermott U; Michiels S; Moscow JA; Tejpar S; McKee T; Lacombe D;
    Nat Rev Drug Discov; 2018 Jan; 17(1):1-2. PubMed ID: 29170471
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cancer stem cell targeted therapy: progress amid controversies.
    Wang T; Shigdar S; Gantier MP; Hou Y; Wang L; Li Y; Shamaileh HA; Yin W; Zhou SF; Zhao X; Duan W
    Oncotarget; 2015 Dec; 6(42):44191-206. PubMed ID: 26496035
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular pathway activation - New type of biomarkers for tumor morphology and personalized selection of target drugs.
    Buzdin A; Sorokin M; Garazha A; Sekacheva M; Kim E; Zhukov N; Wang Y; Li X; Kar S; Hartmann C; Samii A; Giese A; Borisov N
    Semin Cancer Biol; 2018 Dec; 53():110-124. PubMed ID: 29935311
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maurie Markman on the Groundbreaking TAPUR Trial.
    Markman M
    Oncology (Williston Park); 2017 Mar; 31(3):158, 168. PubMed ID: 28299751
    [No Abstract]   [Full Text] [Related]  

  • 34. The evolving potential of companion diagnostics.
    Khoury JD
    Scand J Clin Lab Invest Suppl; 2016; 245():S22-5. PubMed ID: 27433788
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The dark side of ZNF217, a key regulator of tumorigenesis with powerful biomarker value.
    Cohen PA; Donini CF; Nguyen NT; Lincet H; Vendrell JA
    Oncotarget; 2015 Dec; 6(39):41566-81. PubMed ID: 26431164
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Precision medicine: In need of guidance and surveillance.
    Lin JZ; Long JY; Wang AQ; Zheng Y; Zhao HT
    World J Gastroenterol; 2017 Jul; 23(28):5045-5050. PubMed ID: 28811702
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biomarkers of Bad Biology: Curse or a Blessing?
    Banerjee S; Sicklick JK
    Ann Surg Oncol; 2019 Feb; 26(2):318-320. PubMed ID: 30539488
    [No Abstract]   [Full Text] [Related]  

  • 38. The Prospective Incorporation of Molecular Profiling Will Transform Global Cancer Care.
    Marshall JL
    Oncology (Williston Park); 2020 Sep; 34(9):356-357. PubMed ID: 32965666
    [No Abstract]   [Full Text] [Related]  

  • 39. Genomic profiling guides the choice of molecular targeted therapy of pancreatic cancer.
    Frank TS; Sun X; Zhang Y; Yang J; Fisher WE; Gingras MC; Li M
    Cancer Lett; 2015 Jul; 363(1):1-6. PubMed ID: 25890222
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting dynamics of subclones of GI, liver and pancreatic cancers.
    Ziogas DE; Glantzounis G; Liakakos T; Roukos DH
    Expert Rev Gastroenterol Hepatol; 2016 Jul; 10(7):773-6. PubMed ID: 27143511
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.